With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments
Fierce Biotech - 2024-04-18T11:00:00.000Z

Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. | Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. Read this story